title: Endosomolytic reducible polymeric electrolytes for cytosolic protein delivery.
abstract: Despite the numerous vital functions of proteins in the cytosolic compartment, less attention has been paid to the delivery of protein drugs to the cytosol than to the plasma membrane. To address this issue and effectively deliver charged proteins into the cytoplasm, we used endosomolytic, thiol-triggered degradable polyelectrolytes as carriers. The cationic, reducible polyelectrolyte RPC-bPEI(0.8 kDa)2 was synthesized by the oxidative polymerization of thiolated branched polyethyleneimine (bPEI). The polymer was converted to the anionic, reducible polyelectrolyte RPA-bPEI(0.8 kDa)2 by introducing carboxylic acids. The two reducible polyelectrolytes (RPC-bPEI(0.8 kDa)2 and RPA-bPEI(0.8 kDa)2) were complexed with counter-charged model proteins (bovine serum albumin (BSA) and lysozyme (LYZ)), forming polyelectrolyte/protein complexes of less than 200 nm in size at weight ratios (WR) of ≥1. The resultant complexes maintained a proton buffering capacity nearly equivalent to that of the polyelectrolytes in the absence of protein complexation and were cytocompatible with MCF7 human breast carcinoma cells. Under cytosol-mimicking thiol-rich conditions, RPC-bPEI(0.8 kDa)2/BSA and RPA-bPEI(0.8 kDa)2/LYZ complexes increased significantly in size and released the loaded protein, unlike the protein complexes with nonreducible polyelectrolytes (bPEI(25 kDa) and bPEI(25 kDa)COOH). The polyelectrolyte/protein complexes showed cellular uptake similar to that of the corresponding proteins alone, but the former allowed more protein to escape into the cytosol from endolysosomes than the latter as a result of the endosomolytic function of the polyelectrolytes. In addition, the proteins in the polyelectrolyte/protein complexes kept their intrinsic secondary structures. In conclusion, the results show the potential of the designed endosomolytic, reducible polyelectrolytes for the delivery of proteins to the cytosol.
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Chemistry, The University of Utah, Salt Lake City, 84112, USA.
authors.forename: Li
authors.initials: L
authors.lastname: Tian
authors.forename: Han Chang
authors.initials: HC
authors.lastname: Kang
authors.forename: You Han
authors.initials: YH
authors.lastname: Bae
mesh_terms: D001692:Biological Transport; D002021:Buffers; D002264:Carboxylic Acids / Q000737:chemistry / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems; D004573:Electrolytes / Q000737:chemistry / Q000378:metabolism; D011992:Endosomes / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007097:Imines / Q000138:chemical synthesis* / Q000378:metabolism; D061986:MCF-7 Cells; D009113:Muramidase / Q000737:chemistry / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry* / Q000378:metabolism; D010084:Oxidation-Reduction; D010316:Particle Size; D011095:Polyethylenes / Q000138:chemical synthesis* / Q000378:metabolism; D058105:Polymerization; D011485:Protein Binding; D017433:Protein Structure, Secondary; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000378:metabolism; D017186:Titrimetry
chemical_list: D002021:Buffers; D002264:Carboxylic Acids; D004337:Drug Carriers; D004573:Electrolytes; D007097:Imines; D011095:Polyethylenes; D012710:Serum Albumin, Bovine; D009113:Muramidase